Thursday, 22 May 2014

Overview of Disorders of Potassium Concentration

K is the most abundant intracellular cation, but only about 2% of total body K is extracellular. Because most intracellular K is contained within muscle cells, total body K is roughly proportional to lean body mass. An average 70-kg adult has about 3500 mEq of K.
K is a major determinant of intracellular osmolality. The ratio between K concentration in the ICF and ECF strongly influences cell membrane polarization, which in turn influences important cell processes, such as the conduction of nerve impulses and muscle (including myocardial) cell contraction. Thus, relatively small alterations in serum K concentration can have significant clinical manifestations.
In the absence of factors that shift K in or out of cells (see K shifts), the serum K concentration correlates closely with total body K content. Once intracellular and extracellular concentrations are stable, a decrease in serum K concentration of about 1 mEq/L indicates a total K deficit of about 200 to 400 mEq. Patients with K < 3 mEq/L typically have a significant K deficit.

K shifts: 

Factors that shift K in or out of cells include the following:
 

  • Insulin concentrations
  • β-Adrenergic activity
  • Acid-base status
Insulin moves K into cells; high concentrations of insulin thus lower serum K concentration. Low concentrations of insulin, as in diabetic ketoacidosis, cause K to move out of cells, thus raising serum K, sometimes even in the presence of total body K deficiency.
β-Adrenergic agonists, especially selective β2-agonists, move K into cells, whereas β-blockade and α-agonists promote movement of K out of cells.
Acute metabolic acidosis causes K to move out of cells, whereas acute metabolic alkalosis causes K to move into cells. However, changes in serum HCO3 concentration may be more important than changes in pH; acidosis caused by accumulation of mineral acids (nonanion gap, hyperchloremic acidosis) is more likely to elevate serum K. In contrast, metabolic acidosis due to accumulation of organic acids (increased anion gap acidosis) does not cause hyperkalemia. Thus, the hyperkalemia common in diabetic ketoacidosis results more from insulin deficiency than from acidosis. Acute respiratory acidosis and alkalosis affect serum K concentration less than metabolic acidosis and alkalosis. Nonetheless, serum K concentration should always be interpreted in the context of the serum pH (and HCO3 concentration).

K metabolism: 

Dietary K intake normally varies between 40 and 150 mEq/day. In the steady state, fecal losses are usually close to 10% of intake. The remaining 90% is excreted in the urine so alternations in renal K secretion greatly affect K balance.
 


When K intake is > 150 mEq/day, about 50% of the excess K appears in the urine over the next several hours. Most of the remainder is transferred into the intracellular compartment, thus minimizing the rise in serum K. When elevated K intake continues, aldosterone secretion is stimulated and thus renal K excretion rises. In addition, K absorption from stool appears to be under some regulation and may fall by 50% in chronic K excess.
When K intake falls, intracellular K again serves to buffer wide swings in serum K concentration. Renal K conservation develops relatively slowly in response to decreases in dietary K and is far less efficient than the kidneys' ability to conserve Na. Thus, K depletion is a frequent clinical problem. Urinary K excretion of 10 mEq/day represents near-maximal renal K conservation and implies significant K depletion.
Acute acidosis impairs K excretion, whereas chronic acidosis and acute alkalosis can promote K excretion. Increased delivery of Na to the distal nephrons, as occurs with high Na intake or loop diuretic therapy, promotes K excretion.

False K concentrations: 

Pseudohypokalemia, or falsely low serum K, occasionally is found when blood specimens from patients with chronic myelocytic leukemia and a WBC count > 105/μL remain at room temperature before being processed because of uptake of serum K by abnormal leukocytes in the sample. It is prevented by prompt separation of plasma or serum in blood samples.
 


Pseudohyperkalemia, or falsely elevated serum K, is more common, typically occurring due to hemolysis and release of intracellular K. To prevent false results, phlebotomy personnel should not rapidly aspirate blood through a narrow-gauge needle or excessively agitate blood samples. Pseudohyperkalemia can also result from platelet count > 400,000/μL due to release of K from platelets during clotting. In cases of pseudohyperkalemia, the plasma K (unclotted blood), as opposed to serum K, is normal.


Symptoms of Hypokalemic Periodic Paralysis (Plus)

Weakness can affect skeletal, cardiac, smooth, gastrointestinal, respiratory, facial and/or eye muscles (including the muscles of the iris that control entry of light)


These are generalized or reported symptoms. 
Families can exhibit a wide range of features and symptoms
continue here:http://periodicparalysis.blogspot.co.uk/p/symptoms-of-hypokalemic-periodic.html

Thyrotoxic Periodic Paralysis – Clinical Diagnosis and Management

1. Introduction

1.1. DEFINITION

Periodic paralysis comprises a group of neuromuscular diseases in which the patients present with paroxysmal muscle weakness of the limbs. [1] The most common causes are thyrotoxic hypokalemic periodic paralysis (TPP) and familial hypokalemic periodic paralysis (FPP). [1]
Thyrotoxic periodic paralysis (TPP) is a medical emergency characterized by an acute and reversible attack of muscle weakness associated with the hypokalemia. [12] TPP is the most common form of acquired flaccid paralysis in adults with hyperthyroidism and can occur in patients of any ethnicity, [3,4] although it is more frequent in Asian populations. [5] TPP is the newest form of endocrine channelopathy included in the large group of periodic paralysis and should be included in the differential diagnosis of acute muscle weakness in patients seeking emergency care.

Paramyotonia Congenita: Another Form Of Periodic Paralysis

Paramyotonia Congenita: Another Form Of Periodic Paralysis

Paramyotonia Congenita is a form of Periodic Paralysis (PP). I have overlooked this form in my writings and in my book. I now want to describe and explain it, as it is an important form and can accompany all other forms of Periodic Paralysis; Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis and Normokalemic Periodic Paralysis, but usually is seen with Hyperkalemic Periodic Paralysis. It may also occur or manifest as Hyperkalemic Periodic Paralysis and is believed to actually be a form of Hyperkalemic Periodic Paralysis.

Paramyotonia Congenita (PMC), also known as 
Eulenburg Disease, is a rare, hereditary mineral metabolic disorder, which is also called a channelopathy and it affects the muscles used in movement. Caused by certain triggers, the sodium channels close much too slowly and the sodium, potassium, chloride and water continue to flow into the muscles. The skeletal muscles can become stiff, tight, tense or contracted and weak. PMC is caused by mutations in the SCN4A gene, a voltage-gated sodium channel. There is a 100% penetrance. This means if one has one of the mutations for it, they have a 100% chance of having it. In the same family, some members may have mild forms and others may have more extreme cases. It is actually considered to be a form of Hyperkalemic Periodic Paralysis, however, the symptoms can appear from shifting of potassium into low or high ranges or even if potassium shifts within normal levels.  Symptoms can begin shortly after birth or during childhood or at anytime in early adulthood.


Prevalence and Incidence of Hypokalemic periodic paralysis

Prevalance of Hypokalemic periodic paralysis:

1 per 100,000 people suffer from hypokalemic periodic paralysis, Genetics Home Reference website ... see also overview of Hypokalemic periodic paralysis.

Prevalance Rate:

approx 1 in 100,000 or 0.00% or 2,720 people in USA [Source statistic for calcuation: "1 per 100,000 people suffer from hypokalemic periodic paralysis, Genetics Home Reference website" --see also general information about data sources]

Thursday, 21 November 2013

Parálisis periódica hipercaliémica

Parálisis periódica hipercaliémica

¿Qué es la parálisis periódica hiperpotasemia?

Parálisis periódica hipercaliémica es una condición que causa episodios de debilidad muscular extrema o parálisis, generalmente, comienza en la infancia o la niñez temprana. Muy a menudo, estos episodios implican una incapacidad temporal para mover los músculos de los brazos y las piernas. Episodios tienden a aumentar en frecuencia hasta mediados de la edad adulta, después de los cuales se producen con menor frecuencia. Los factores que pueden desencadenar ataques incluyen reposo después del ejercicio, los alimentos ricos en potasio como los plátanos y las patatas, el estrés, la fatiga, el alcohol, el embarazo, la exposición a temperaturas frías, ciertos medicamentos, y los períodos sin comida (en ayunas). La fuerza muscular vuelve a la normalidad entre los ataques, aunque muchas personas afectadas continúan experimentando rigidez leve (miotonía), sobre todo en los músculos de la cara y las manos.
La mayoría de las personas con parálisis periódica hiperpotasemia han aumentado los niveles de potasio en su sangre (hiperpotasemia) durante los ataques. Resultados de hiperpotasemia cuando los músculos débiles o paralizados liberan iones de potasio en el torrente sanguíneo. En otros casos, los ataques están asociados con los niveles de potasio en la sangre normales (normocalemia). La ingestión de potasio puede provocar ataques en las personas afectadas, incluso si los niveles de potasio en la sangre no sube.
¿Qué tan común es la parálisis periódica hiperpotasemia?

Parálisis periódica hipercaliémica afecta a alrededor de 1 de cada 200.000 personas.
¿Qué genes están relacionados con la parálisis periódica hiperpotasemia?

Las mutaciones en el gen SCN4A pueden causar parálisis periódica hipercalémica. El gen SCN4A proporciona instrucciones para hacer una proteína que juega un papel esencial en los músculos se utiliza para el movimiento (músculos esqueléticos). Para que el cuerpo se mueve normalmente, estos músculos deben tensa (contrato) y relajarse de una manera coordinada. Uno de los cambios que ayuda a las contracciones musculares de activación es el flujo de átomos cargados positivamente (iones), incluyendo sodio, en las células musculares. La proteína SCN4A forma canales que controlan el flujo de iones de sodio en estas células.
Las mutaciones en el gen SCN4A alteran la estructura normal y la función de los canales de sodio. Los canales alterados permanecen abiertas por mucho tiempo o no permanecen cerrados el tiempo suficiente, lo que permite más flujo de iones de sodio en las células musculares. Este aumento de los iones de sodio provoca la liberación de potasio de las células musculares, lo que hace más canales de sodio para abrir y estimula el flujo de iones de sodio aún más en estas células. Estos cambios en el transporte de iones reducen la capacidad de los músculos esqueléticos se contraigan, lo que lleva a episodios de debilidad muscular o parálisis.
En 30 a 40 por ciento de los casos, la causa de parálisis periódica hipercalémica es desconocido. Los cambios en otros genes, que no han sido identificados, probablemente causan la enfermedad en estos casos.
Lea más sobre el gen SCN4A.
¿Cómo se heredan parálisis periódica hiperpotasemia?

Esta condición se hereda en un patrón autosómico dominante, lo que significa que una copia del gen alterado en cada célula es suficiente para causar el trastorno.
En la mayoría de los casos, una persona afectada tiene un padre con la enfermedad.
¿Dónde puedo encontrar información sobre el diagnóstico o el tratamiento de la parálisis periódica hiperpotasemia?

Estos recursos abordan el diagnóstico o tratamiento de parálisis periódica hiperpotasemia y pueden incluir proveedores de tratamiento.
Revisión Gene: hipercaliémica Parálisis Periódica Tipo 1
Pruebas genéticas Registro: parálisis periódica familiar hipercalémica
Genetic Testing Registro: hipercaliémica Parálisis Periódica Tipo 1
Lab Tests Online: Potasio
MedlinePlus Enciclopedia: Parálisis Periódica hipercaliémica
Parálisis Periódica Internacional: ¿Cómo se diagnostica la parálisis periódica?
También puede encontrar información sobre el diagnóstico o el tratamiento de la parálisis periódica hiperpotasemia en los recursos educativos y de apoyo para pacientes.
Información general sobre el diagnóstico y tratamiento de las enfermedades genéticas está disponible en el manual. Lea más acerca de las pruebas genéticas, en particular la diferencia entre las pruebas clínicas y ensayos de investigación.
Para localizar a un proveedor de atención médica, consulte ¿Cómo puedo encontrar un profesional de la genética en mi área? en el manual.
¿Dónde puedo encontrar información adicional acerca de la parálisis periódica hiperpotasemia?


GRACIAS: http://ghr.nlm.nih.gov/condition/hyperkalemic-periodic-paralysis

Hyperkalemic periodic paralysis

What is hyperkalemic periodic paralysis?

Hyperkalemic periodic paralysis is a condition that causes episodes of extreme muscle weakness or paralysis, usually beginning in infancy or early childhood. Most often, these episodes involve a temporary inability to move muscles in the arms and legs. Episodes tend to increase in frequency until mid-adulthood, after which they occur less frequently. Factors that can trigger attacks include rest after exercise, potassium-rich foods such as bananas and potatoes, stress, fatigue, alcohol, pregnancy, exposure to cold temperatures, certain medications, and periods without food (fasting). Muscle strength usually returns to normal between attacks, although many affected people continue to experience mild stiffness (myotonia), particularly in muscles of the face and hands.

Most people with hyperkalemic periodic paralysis have increased levels of potassium in their blood (hyperkalemia) during attacks. Hyperkalemia results when the weak or paralyzed muscles release potassium ions into the bloodstream. In other cases, attacks are associated with normal blood potassium levels (normokalemia). Ingesting potassium can trigger attacks in affected individuals, even if blood potassium levels do not go up.

How common is hyperkalemic periodic paralysis?

Hyperkalemic periodic paralysis affects an estimated 1 in 200,000 people.

What genes are related to hyperkalemic periodic paralysis?

Mutations in the SCN4A gene can cause hyperkalemic periodic paralysis. The SCN4A gene provides instructions for making a protein that plays an essential role in muscles used for movement (skeletal muscles). For the body to move normally, these muscles must tense (contract) and relax in a coordinated way. One of the changes that helps trigger muscle contractions is the flow of positively charged atoms (ions), including sodium, into muscle cells. The SCN4A protein forms channels that control the flow of sodium ions into these cells.

Mutations in the SCN4A gene alter the usual structure and function of sodium channels. The altered channels stay open too long or do not stay closed long enough, allowing more sodium ions to flow into muscle cells. This increase in sodium ions triggers the release of potassium from muscle cells, which causes more sodium channels to open and stimulates the flow of even more sodium ions into these cells. These changes in ion transport reduce the ability of skeletal muscles to contract, leading to episodes of muscle weakness or paralysis.

In 30 to 40 percent of cases, the cause of hyperkalemic periodic paralysis is unknown. Changes in other genes, which have not been identified, likely cause the disorder in these cases.

Read more about the SCN4A gene.

How do people inherit hyperkalemic periodic paralysis?

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

In most cases, an affected person has one parent with the condition.

Where can I find information about diagnosis or management of hyperkalemic periodic paralysis?

These resources address the diagnosis or management of hyperkalemic periodic paralysis and may include treatment providers.

You might also find information on the diagnosis or management of hyperkalemic periodic paralysis in Educational resources and Patient support.

General information about the diagnosis and management of genetic conditions is available in the Handbook. Read more about genetic testing, particularly the difference between clinical tests and research tests.

To locate a healthcare provider, see How can I find a genetics professional in my area? in the Handbook.

Where can I find additional information about hyperkalemic periodic paralysis?


THANKS :   http://ghr.nlm.nih.gov/condition/hyperkalemic-periodic-paralysis

Hyperkalemic periodic paralysis

Hyperkalemic periodic paralysis (HYPP, HyperKPP) is a genetic disorder that occurs in horses and humans, where it is also known as Impressive syndrome. It is aninherited autosomal dominant disorder that affects sodium channels in muscle cells and the ability to regulate potassium levels in the blood. It is most commonly associated with horses, but occurs in humans, where it may be called Gamstorp episodic adynamy. It is characterized by muscle hyperexcitability or weakness which, exacerbated by potassiumor cold, can lead to uncontrolled shaking followed by paralysis. Onset in humans usually occurs in early childhood.

The mutation which causes this disorder is dominant on SCN4A with linkage to thesodium channel expressed in muscle. The mutation causes single amino acid changes in parts of the channel which are important for inactivation. In the presence of high potassium levels, including those induced by diet, sodium channels fail to inactivate properly.

Equine hyperkalaemic periodic paralysis occurs in 1 in 50 quarter horses and can be traced to a single ancestor, a stallion namedImpressive.



Thanks:   http://en.wikipedia.org/wiki/Hyperkalemic_periodic_paralysis

Monday, 4 November 2013

Trastornos del potasio

1. Introducción
Las alteraciones del metabolismo del potasio se encuentran entre las más frecuentes en la práctica clínica. Su espectro de gravedad es variable, desde la hipopotasemia leve inducida por diuréticos a la hiperpotasemia grave de consecuencias fatales. Tanto la hipopotasemia como la hiperpotasemia ocasionan alteraciones de la polarización de la membrana celular que dan lugar a diversas manifestaciones clínicas, de las que las más graves son las que afectan al sistema cardiovascular.


2. Factores reguladores de la homeostasis del potasio
La concentración de potasio plasmático es el resultado de la relación entre su ingesta, eliminación y distribución transcelular. Los requerimientos mínimos diarios de potasio son de unos 1.600-2.000 mg (40-50 mmol; 40 mg = 1 mmol). Su principal vía de eliminación es la renal. Aproximadamente el 80% del potasio ingerido es excretado por los riñones, el 15% por el tracto gastrointestinal y el 5% restante por el sudor.